Looking for growth without the hefty price tag? Consider NYSE:GMED.

Uncover the potential of GLOBUS MEDICAL INC - A (NYSE:GMED), a growth stock that our stock screener found to be reasonably priced. NYSE:GMED is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.

Assessing Growth for NYSE:GMED

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NYSE:GMED was assigned a score of 7 for growth:

• The Earnings Per Share has grown by an nice 12.56% over the past year.
• Looking at the last year, GMED shows a very strong growth in Revenue. The Revenue has grown by 53.36%.
• Measured over the past years, GMED shows a quite strong growth in Revenue. The Revenue has been growing by 17.08% on average per year.
• The Earnings Per Share is expected to grow by 16.87% on average over the next years. This is quite good.
• Based on estimates for the next years, GMED will show a quite strong growth in Revenue. The Revenue will grow by 17.14% on average per year.
• When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Unpacking NYSE:GMED's Valuation Rating

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NYSE:GMED scores a 6 out of 10:

• Based on the Price/Earnings ratio, GMED is valued cheaply inside the industry as 84.69% of the companies are valued more expensively.
• Based on the Price/Forward Earnings ratio, GMED is valued cheaply inside the industry as 87.24% of the companies are valued more expensively.
• 79.08% of the companies in the same industry are more expensive than GMED, based on the Enterprise Value to EBITDA ratio.
• Based on the Price/Free Cash Flow ratio, GMED is valued cheaper than 80.61% of the companies in the same industry.
• The decent profitability rating of GMED may justify a higher PE ratio.
• A more expensive valuation may be justified as GMED's earnings are expected to grow with 19.90% in the coming years.

Looking at the Health

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NYSE:GMED was assigned a score of 6 for health:

• An Altman-Z score of 5.08 indicates that GMED is not in any danger for bankruptcy at the moment.
• The Altman-Z score of GMED (5.08) is better than 78.57% of its industry peers.
• The Debt to FCF ratio of GMED is 2.53, which is a good value as it means it would take GMED, 2.53 years of fcf income to pay off all of its debts.
• Looking at the Debt to FCF ratio, with a value of 2.53, GMED belongs to the top of the industry, outperforming 89.80% of the companies in the same industry.
• GMED has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
• A Current Ratio of 4.88 indicates that GMED has no problem at all paying its short term obligations.
• Looking at the Current ratio, with a value of 4.88, GMED is in the better half of the industry, outperforming 67.86% of the companies in the same industry.
• A Quick Ratio of 2.72 indicates that GMED has no problem at all paying its short term obligations.

Profitability Assessment of NYSE:GMED

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:GMED was assigned a score of 6 for profitability:

• With a decent Return On Assets value of 2.42%, GMED is doing good in the industry, outperforming 75.00% of the companies in the same industry.
• The Return On Equity of GMED (3.07%) is better than 74.49% of its industry peers.
• Looking at the Return On Invested Capital, with a value of 3.28%, GMED is in the better half of the industry, outperforming 73.98% of the companies in the same industry.
• Looking at the Profit Margin, with a value of 7.83%, GMED belongs to the top of the industry, outperforming 81.63% of the companies in the same industry.
• GMED has a better Operating Margin (12.87%) than 83.16% of its industry peers.
• GMED has a Gross Margin of 65.05%. This is in the better half of the industry: GMED outperforms 69.39% of its industry peers.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

Our latest full fundamental report of GMED contains the most current fundamental analsysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.